Subject Predicate Object
vNDj1Qzi
a
Resource
Answer
Written answer
answer has question
kCNuz6Cw
answer has answering person
Stephen Charles Brine
answer text
<p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) develops authoritative, independent and evidence-based recommendations for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE develops technology appraisal guidance for the NHS on all new cancer drugs, including for neuroblastoma, and NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.</p><p> </p><p>NICE is currently appraising the drug dinutuximab beta for use in the treatment of high-risk neuroblastoma and has not yet issued final guidance. NICE recently consulted on its draft recommendations and will take the comments it received fully into account in developing its final guidance.</p><p> </p><p>NICE has also been asked to appraise the drug dinutuximab for use in the treatment of high-risk neuroblastoma but the manufacturer asked for the drug’s marketing authorisation to be withdrawn because of supply issues and NICE’s appraisal has now been suspended.</p>
answer given date
answer has answering body
Department of Health and Social Care
written answer has answering body
Department of Health and Social Care
Department of Health and Social Care
answering body has written answer
vNDj1Qzi
answering body has answer
vNDj1Qzi
kCNuz6Cw
question has answer
vNDj1Qzi
Stephen Charles Brine
answering person has answer
vNDj1Qzi